Loading…
Employees: 508
Size Nanosonics (NAN.AX) is an Australia Health Care company (Medical Specialties) with a market value of $599M, the 240th largest of 316 Australia companies the cockpit tracks. Shares closed at A$2.89 on 6 Nov 2026.
Performance Over six months the shares fell 13.2%, against -13.5% for the median peer and +4.1% for the Australia market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 2.6% over the last twelve months (peer median +10.2%); the operating margin is 7.4% (peer median 8.5%).
Valuation It trades at 90.3× forward earnings against a peer median of 23.9× (most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 34% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.5 points above its cost of capital (10.8% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$203M | A$203M | A$198M | A$172M | A$168M |
| Revenue growth | — | +3% | +16% | +2% | — |
| Gross profit | A$156M | A$149M | A$148M | A$127M | A$126M |
| EBITDA | A$23.7M | A$23.7M | A$24.5M | A$16.0M | A$25.1M |
| Net income | A$17.8M | A$17.8M | A$20.7M | A$13.0M | A$19.9M |
| Free cash flow | A$17.4M | A$17.4M | A$35.3M | A$20.3M | A$19.7M |
| Capital expenditure | A$5.14M | A$5.14M | A$8.72M | A$2.52M | A$3.57M |
| Total debt | n/a | A$23.1M | A$7.69M | A$9.30M | A$10.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NAN.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.2% | -5.1% | 6th highest of 20 |
| 6-month return | -13.2% | -13.5% | 10th highest of 20 |
| Distance from 52-week high | -34.3% | -37.3% | 9th highest of 20 |
| Revenue growth (TTM) | +2.6% | +10.2% | 7th lowest of 20 |
| Operating margin | 7.4% | 8.5% | 10th lowest of 20 |
| Forward P/E | 90.3× | 23.9× | most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 34.4% | 7.4% | 2nd most demanding of 12 |
| Growth delivered (Del g) | +6.7% | +12.0% | 6th lowest of 12 |
| Hurdle (Req g minus delivered) | +27.7 pp | +0.5 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | +1.5 pp | -0.7 pp | 8th highest of 18 |
| EV / EBITDA | 30.9× | 19.2× | most expensive of 5 |
| Net debt / EBITDA | -5.6× | -1.0× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 90.3× | 34.4% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | n/a | 17.3% | -19.8% |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 30.5× | -1.8% | +14.5% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 22.6× | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 12.3× | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 20.8× | 7.8% | +12.0% |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 19.8× | 1.7% | +27.8% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 25.2× | 11.6% | +6.5% |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 63.8× | 2.7% | -13.2% |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | n/a | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | n/a | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | n/a | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 21.7× | 22.3% | +4.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 25.2× | 6.3% | +24.4% |